HPLC Verified
Purity confirmed by High-Performance Liquid Chromatography at an accredited EU laboratory.

5mg ERR agonist research compound
SLU-PP-332 is a potent synthetic agonist of estrogen-related receptor alpha (ERRα), a nuclear transcription factor that functions as a master regulator of mitochondrial biogenesis, oxidative metabolism, and exercise-adaptive gene expression. Its designation as an "exercise mimetic" reflects preclinical data demonstrating that its pharmacological activation of ERRα recapitulates elements of the transcriptional and physiological response to endurance exercise — without the contractile activity itself.
ERRα (estrogen-related receptor alpha, gene name ESRRA) is a member of the nuclear receptor superfamily that was classified as an orphan receptor due to the absence of an identified endogenous ligand. Despite lacking a classical hormone ligand, ERRα is constitutively active and controls the expression of hundreds of genes in oxidative metabolism pathways — particularly in tissues with high energy demand such as skeletal muscle, heart, and brown adipose tissue. Its transcriptional targets include PGC-1α, cytochrome c oxidase subunits, fatty acid oxidation enzymes, and genes governing mitochondrial biogenesis. Exercise-induced PGC-1α expression potently coactivates ERRα, establishing this nuclear receptor as a critical node in the exercise-response transcriptional network.
SLU-PP-332 was developed by Thomas Burris's group at Washington University as a highly selective, cell-permeable ERRα agonist. It binds to the ligand-binding domain of ERRα and stabilises the receptor in an active conformation that recruits transcriptional coactivators, reproducing many of the genomic responses normally triggered by exercise-induced PGC-1α coactivation. ERRβ and ERRγ selectivity profiling confirms that SLU-PP-332 has substantially greater activity at ERRα than at the related receptor subtypes, making it a useful tool for dissecting ERRα-specific biology.
Preclinical studies have reported that SLU-PP-332 administration in sedentary mice upregulates oxidative phosphorylation gene sets, increases mitochondrial content in skeletal muscle, and improves exercise capacity (assessed by treadmill running distance) beyond that achievable by the vehicle-treated sedentary controls. These findings have generated significant interest in SLU-PP-332 as a pharmacological tool for studying the molecular basis of exercise adaptation, particularly in contexts where physical exercise is not feasible.
Beyond exercise biology, SLU-PP-332 has potential applications as a research tool in cardiac metabolism (ERRα is highly expressed in cardiomyocytes), brown adipose thermogenesis research, and studies of mitochondrial biogenesis in ageing models. Its well-characterised selectivity profile and cell permeability make it a practical in vitro and in vivo tool for nuclear receptor biology investigations.
This content is for informational purposes only and reflects the state of preclinical research. It does not constitute medical advice, endorsement of human use, or therapeutic claims of any kind.
Purity confirmed by High-Performance Liquid Chromatography at an accredited EU laboratory.
Every batch meets or exceeds 98% purity. CoA available for verification before dispatch.
Each vial is traceable to its synthesis batch, testing date, and analytical records.
European stock stored at optimal temperature from synthesis to dispatch.
Orders ship from EU stock within 48 hours with discrete, temperature-appropriate packaging.
Certificate of Analysis issued for every batch, available for download on request.
Peer-reviewed research supporting SLU-PP-332 investigation.
Foundational characterisation of ERRα's role in metabolic gene regulation, establishing the receptor's broad transcriptional control over oxidative phosphorylation and fatty acid oxidation gene networks. Pharmacological modulation of ERRα activity is demonstrated to alter the expression of hundreds of metabolic genes in muscle and adipose tissue models.
View on PubMedGenome-wide ChIP-chip analysis mapping ERRα binding sites across the cardiac genome. The study identifies ERRα as a master coordinator of cardiac metabolic gene expression, with binding enrichment at promoters of mitochondrial electron transport chain components, fatty acid oxidation enzymes, and TCA cycle genes — establishing the importance of ERRα biology for cardiac metabolism research.
View on PubMedInvestigation of ERRα's role in skeletal muscle development and function using ERRα knockout models. Loss of ERRα impairs myogenic differentiation, reduces mitochondrial content, and compromises oxidative metabolism — phenotypes that mirror elements of sarcopenic muscle in ageing, providing functional context for pharmacological ERRα activation as a potential tool in muscle biology research.
View on PubMedMedicinal chemistry study reporting the identification and characterisation of synthetic ERRα agonists including structural relatives of SLU-PP-332. SAR analysis defines key pharmacophore features for ERRα agonism and selectivity, and in vitro metabolic profiling confirms activation of oxidative phosphorylation gene programmes consistent with ERRα's transcriptional role.
View on PubMedAll studies referenced are independent third-party research. UNIK LAB makes no claims regarding the therapeutic efficacy of any compound and does not represent or endorse the conclusions of cited studies. All referenced research was conducted under controlled laboratory or clinical conditions; results may not be predictive of effects in other experimental contexts.
Answers to the most frequently asked questions about SLU-PP-332.
Other Metabolic research compounds from our catalogue.
SLU-PP-332 selectively binds the ligand-binding domain of ERRα, stabilising the receptor in an active conformation that recruits transcriptional coactivators. This pharmacological activation of the constitutively active orphan nuclear receptor reproduces genomic responses normally triggered by exercise-induced PGC-1α coactivation.
SLU-PP-332 recapitulates the oxidative phosphorylation gene expression programme associated with endurance exercise adaptation without requiring contractile activity. Preclinical studies document upregulation of TFAM, COX5A, and ACADM — canonical ERRα target genes central to mitochondrial biogenesis and fatty acid oxidation.
Skeletal muscle mitochondrial content increases following SLU-PP-332 administration in sedentary rodents, as assessed by MitoTracker staining, electron microscopy, and Seahorse XF mitochondrial respiration assays. These observations position ERRα agonism as a pharmacological strategy for studying the regulation of skeletal muscle oxidative capacity.
SLU-PP-332-treated sedentary mice demonstrate improved treadmill running distance compared to vehicle-treated controls, with gene set enrichment analysis confirming activation of oxidative phosphorylation and fatty acid oxidation programmes. These data establish the compound as a functional exercise mimetic at the physiological level.
ERRα is among the highest-expressed nuclear receptors in cardiomyocytes and brown adipose tissue, tissues with critical dependence on oxidative metabolism. SLU-PP-332 serves as a research tool for investigating ERRα-mediated regulation of cardiac energy metabolism and thermogenic adipose biology.
ERRα (estrogen-related receptor alpha) is a nuclear transcription factor that constitutively controls gene expression in oxidative phosphorylation, fatty acid oxidation, mitochondrial biogenesis, and thermogenesis pathways. During exercise, PGC-1α — the primary exercise-responsive transcriptional coactivator — potently activates ERRα, making this receptor a central node in the transcriptional programme that underlies exercise-induced adaptation. Pharmacological ERRα agonism is thus a strategy for studying which elements of exercise adaptation are mediated through this specific receptor.
An exercise mimetic is a compound that activates exercise-responsive signalling pathways pharmacologically, producing some of the molecular and physiological adaptations normally induced by physical activity. SLU-PP-332 achieves this by directly activating ERRα — bypassing the upstream signals (contractile activity, calcium flux, AMPK activation) that normally converge on PGC-1α/ERRα. This makes it useful for studying the downstream transcriptional consequences of ERRα activation in isolation from the pleiotropic effects of exercise itself.
SLU-PP-332 demonstrates preferential activity at ERRα compared to the closely related ERRβ and ERRγ subtypes. Selectivity profiling data show substantially greater potency at ERRα, making it a useful tool for receptor subtype-specific studies. However, as with all pharmacological tools, researchers should validate results with genetic controls (ERRα knockout or knockdown) and orthogonal approaches to confirm ERRα-specific interpretations.
Common assays include: (1) reporter gene assays using ERRα-responsive promoter elements (e.g., ERRE-luciferase) to confirm receptor activation; (2) qRT-PCR for ERRα target genes (TFAM, COX5A, ACADM, PDK4) in muscle cell lines; (3) Seahorse XF analysis for oxygen consumption rate and extracellular acidification rate as functional mitochondrial readouts; (4) MitoTracker staining and electron microscopy for mitochondrial content assessment.
Primary models include C57BL/6 mice on standard diet (for baseline metabolic characterisation), diet-induced obese mice (for metabolic dysfunction models), aged mice (for muscle function studies), and ERRα knockout mice (for mechanism-of-action validation). Treadmill endurance testing, grip strength measurement, and whole-body calorimetry are the most common functional readouts in in vivo studies.
SLU-PP-332 (MW 427.49 Da, small molecule) should be stored at 2–8°C as a dry powder, protected from light. It is typically reconstituted in DMSO at 10–100 mM stock concentrations, with further dilution in aqueous media for cell culture applications. Final DMSO concentration in cell culture should be kept below 0.1% to avoid solvent cytotoxicity. Stability in DMSO stock solution at 2–8°C is approximately 12 months.
ERRα is most highly expressed in tissues with high oxidative energy demand: skeletal muscle (particularly slow-twitch oxidative fibres), heart, brown adipose tissue, kidney, and brain. Its expression is also significant in liver and intestine. This tissue distribution pattern explains the compound's primary research applications in muscle metabolism, cardiac biology, and adipose thermogenesis — all tissues where mitochondrial function is critical to tissue-specific physiology.